Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Eloxx Pharmaceuticals, Inc. (ELOX)

Eloxx Adds Geno Germano to Board and Names T.R. Srinivas Chief Medical Officer

Neutral Impact 2 of 5 leadership Written later

Eloxx Pharmaceuticals expanded its board from five to six directors on October 19, 2026, appointing Geno J. Germano, a former Pfizer group president, as an independent director. On October 20, the company also announced the appointment of T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer and finalized the design of its Phase 2 EXPRESS trial of exaluren in ADPKD. The filing contains no financial results or guidance.

Key points

  • On October 19, 2026, the board increased its size from five to six and appointed Geno J. Germano to the new seat, with a term ending at the 2027 annual meeting.
  • Germano received an option grant for up to 13,587 shares at an exercise price of $12.50, vesting monthly over 24 installments.
  • T.R. Srinivas, M.D., was appointed Senior Vice President and Chief Medical Officer, as announced October 20, 2026.
  • The EXPRESS Phase 2 trial is designed to enroll about 60 adults; first patient dosing is expected in the third quarter of 2027 and topline data in the first half of 2029.

The filing

CompanyEloxx Pharmaceuticals, Inc. (ELOX)
Form8-K, current report
Filed with the SECOct 21, 2026, 7:31 PM ET
Accession number0001193125-26-428116

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.